Xenetic Biosciences annual free cash flow
2013
2013
2014
2015
2016
2017
2018
Xenetic Biosciences Free Cash Flow (FCF) History (XBIO)
Xenetic Biosciences reported −$6.5M in free cash flow for fiscal 2018, a decrease of $7.9M from the previous fiscal year.
View full Xenetic Biosciences company overviewXenetic Biosciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2018 | 2018-12-31 | −$6.5M | −$7.9M | — | — |
| 2017 | 2017-12-31 | $1.5M | $10.3M | — | +19.58% |
| 2016 | 2016-12-31 | −$8.8M | −$3.5M | — | −293.47% |
| 2015 | 2015-12-31 | −$5.3M | $7.4M | — | — |
| 2014 | 2014-12-31 | −$12.7M | −$6.6M | — | — |
| 2013 · Dec 31 | 2013-12-31 | −$6.1M | −$6.2M | — | −613.07% |
| 2013 · Aug 31 | 2013-08-31 | $68,109 | — | — | +70.29% |
Xenetic Biosciences quarterly free cash flow
Q3.12
Q2.13
Q3.13
Q3.13
Q3.13
Q1.14
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2018 | 2018-12-31 | −$1.0M | −$5.9M | — | — |
| Q3 2018 | 2018-09-30 | −$1.7M | −$30,938 | — | — |
| Q2 2018 | 2018-06-30 | −$2.1M | −$96,577 | — | — |
| Q1 2018 | 2018-03-31 | −$1.7M | −$1.9M | — | — |
| Q4 2017 | 2017-12-31 | $4.8M | $9.5M | — | — |
| Q3 2017 | 2017-09-30 | −$1.6M | −$608,308 | — | −1926.12% |
| Q2 2017 | 2017-06-30 | −$2.0M | −$632,135 | — | — |
| Q1 2017 | 2017-03-31 | $275,380 | $2.1M | — | — |
| Q4 2016 | 2016-12-31 | −$4.6M | −$3.5M | — | — |
| Q3 2016 | 2016-09-30 | −$1.0M | $926,500 | — | — |
| Q2 2016 | 2016-06-30 | −$1.4M | −$1.2M | — | — |
| Q1 2016 | 2016-03-31 | −$1.8M | $246,730 | — | — |
| Q4 2015 | 2015-12-31 | −$1.1M | $1.6M | — | — |
| Q3 2015 | 2015-09-30 | −$2.0M | $733,999 | — | — |
| Q2 2015 | 2015-06-30 | −$195,223 | $3.0M | — | — |
| Q1 2015 | 2015-03-31 | −$2.0M | $2.1M | — | — |
| Q4 2014 | 2014-12-31 | −$2.7M | −$2.3M | — | — |
| Q3 2014 | 2014-09-30 | −$2.7M | −$425,570 | — | — |
| Q2 2014 | 2014-06-30 | −$3.2M | −$2.4M | — | — |
| Q1 2014 · Mar 31 | 2014-03-31 | −$4.1M | −$4.2M | — | — |
| Q1 2014 · Nov 30 | 2013-11-30 | −$385,644 | $560,727 | — | −17779.81% |
| Q3 2013 · Sep 30 | 2013-09-30 | −$2.3M | −$2.3M | — | — |
| Q3 2013 · Jun 30 | 2013-06-30 | −$845,563 | — | — | −84.56% |
| Q3 2013 · May 31 | 2013-05-31 | $17,206 | — | — | +43.65% |
| Q2 2013 · Mar 31 | 2013-03-31 | −$946,371 | — | — | — |
| Q3 2012 | 2012-05-31 | −$13,299 | — | — | −36.51% |
Xenetic Biosciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$6.1M to −$6.5M, a net decrease of $333,301. Xenetic Biosciences's latest reported quarter, Q4 2018, generated −$1.0M in free cash flow, a decrease of $5.9M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Xenetic Biosciences filings at SEC.gov ↗